Special Issue

Risk Prediction and Novel Biomarker Discovery of Chronic Diseases by Advanced Methodologies in Lipidomics and Metabolomics

Message from the Guest Editors

Dear colleagues,

Chronic diseases are complex conditions. Some clinical biomarkers lack the efficiency of detecting the pre-disease stage. And the mechanisms of some chronic diseases are not well understood. In this context, discovering novel biomarkers for early-stage disease diagnosis and risk prediction years before the disease onset can greatly benefit disease-affected populations. Metabolomics, aimed at the systematic measurement of all small molecules from a single biological sample, has been matured as an essential tool for such a purpose from different aspects. Untargeted metabolomics can provide a complete metabolic signature for novel biomarker discovery or understanding the fundamental mechanisms resulting in metabolic-state perturbations. Targeted metabolomics can provide a quantitative view of molecular targets within a pathway with more accurate information of metabolite alterations.

Therefore, this Special Issue seeks to bring together the state-of-the-art research on understanding and predicting the risk of disease progress by metabolomics/lipidomics. Works on innovative metabolomics methodologies for chronic diseases are also highly welcomed.

Guest Editors

Dr. Ying Zhang

BioMarin Pharmaceuticals, Inc., San Rafael, CA 94901, USA

Dr. Kang Chen

College of Food Science and Engineering, Ningbo University, Ningbo 315211, China

Dr. Jun Ding

Wuhan Botanical Garden, Chinese Academy of Sciences, Wuhan 430074, China

Deadline for manuscript submissions

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/214712

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).